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Intracoronary Optical Diagnostics
Current Status, Limitations, and Potential
Harry C. Lowe, MBCHB, PHD,* Jagat Narula, MD, PHD,† James G. Fujimoto, PHD,‡
k-Kyung Jang, MD, PHD§
Sydney, New South Wales, Australia; Irvine, California; and Boston, Massachusetts
Optical coherence tomography (OCT), is a novel intravascular imaging modality analogous to intravas-
cular ultrasound but uses light instead of sound. This review details the background, development,
and status of current investigation using OCT, and discusses advantages, limitations, and likely future
developments. It provides indications for possible future clinical use, and places OCT in the context of
current intravascular imaging in what is a rapidly changing ﬁeld of investigation. (J Am Coll Cardiol
Intv 2011;4:1257–70) © 2011 by the American College of Cardiology Foundationo
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mOptical coherence tomography (OCT), like intra-
vascular ultrasound (IVUS) nearly 2 decades ago, is
changing the way we see coronary pathophysiol-
ogy. The detail with which coronary pathophysi-
ology is viewed by this intravascular imaging mo-
dality is unprecedented, such that we are only now
just beginning to establish how this imaging infor-
mation might be best used to guide management
and influence patient outcomes. This review,
therefore, describes the current status of coronary
optical diagnosis with OCT, in what is already a
rapidly evolving and dynamic field of intracoronary
imaging.
OCT Technology
OCT is an imaging technology analogous to IVUS
but uses light instead of sound. It was first de-
scribed by Huang et al. (1) in 1991, with its first
pplication as single-plane cross-sectional imaging
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August 4, 2011, accepted August 18, 2011.f the retina. OCT has since become an estab-
ished imaging modality in clinical ophthalmology
2), and its biomedical applications have broadened
o include gastrointestinal, dermatological, and
ntravascular imaging (3–5). Intravascular imaging
as progressed to the stage where commercially
vailable systems are now approved for use in
urope, Asia, and Australasia, and was recently
pproved in the United States.
The light source used for OCT imaging is in the
ear-infrared range, around 1,300-nm wavelength,
elected as a compromise to achieve both penetra-
ion and delineation of vascular structures. Images
re formed by measuring the magnitude and echo
ime delay of a reflected backscattered light signal
n a manner analogous to IVUS. However, since
he speed of light (3 108 m/s) is several orders of
agnitude faster than that of sound (1.5  103
m/s), an interferometer is required to record the
reflected light echoes (4). The interferometer splits
the emitted light source into a reference and
sample beam; the reference beam is directed to a
reference mirror at known distance, the sample
beam is directed to the structures of interest. The
sample beam is then reflected back to a detector
where it is summed with the reference beam,
producing interference (4,6) (Fig. 1A).
Early commercially available versions of the
technology used time domain (TD) detection. TD
OCT employs a broadband light source with
wavelengths centered around 1,300 nm, and a
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1258reference mirror that is scanned to sequentially measure
echoes from different depths (6,7). Currently available
systems use a much higher speed method, known as frequency
or Fourier domain (FD) detection. FD OCT uses an interfer-
ometer with a stationary reference mirror, but the light source
frequency or wavelength is rapidly swept in time across 1,250
to 1,350 nm, such that received, reflected signals echo signals
from different depths produced by different frequencies from
the interferometer. Spatial features are encoded in frequency,
in a manner somewhat analogous to magnetic resonance
imaging. Axial depth profiles are then reconstructed by Fourier
transformation. FD OCT thus essentially measures all echoes
of light from different depths simultaneously, rather than
sequentially as in TD OCT (Fig. 1B). FD OCT, therefore,
achieves a dramatic improvement
in sensitivity, enabling imaging
speeds that are 10 times faster
than TD OCT (6,8). This has
been a key advance in clinical appli-
cability, meaning that image acqui-
sition is now possible during a con-
trast or saline flush lasting 3 to 5 s.
OCT Image Acquisition
Since blood strongly scatters
light, intravascular OCT re-
quires a blood-free field lasting
several seconds to allow imag-
ing. In the earlier TD OCT
systems, this was achieved either
by injecting continuous saline/
contrast flushes through the
guiding or delivery catheters, or
by using a proximal balloon oc-
clusion of the vessel with distal
saline/contrast injection. These
techniques are safe, including in
patients with acute coronary
syndromes (ACS), but may be
time-consuming, and require a high degree of operator
expertise (9,10).
Conversely, FD OCT systems do not require proximal
occlusion. The coronary vessel is transiently rendered free of
blood by a bolus injection of saline, contrast, or other
solution, injected at rates of 2 to 4 ml/s, and an automated
20 mm/s pullback within a monorail rapid exchange cath-
eter allows imaging of a 6-cm-long coronary segment
during a 3-s injection (8). The monorail rapid exchange
catheter is compatible with 6-F guiding catheters, and
can be conveniently incorporated into most interventional
procedures. A summary of the characteristics of the FD OCT
and TD OCT systems are shown in Table 1 (11). FD systems
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
FD  Fourier domain
IVUS  intravascular
ultrasound
NI  neointima
STEMI  non–ST-segment
levation myocardial
nfarction
CT  optical coherence
omography
CI  percutaneous
oronary intervention
AP  stable angina
ectoris
TEMI  ST-segment
levation myocardial
nfarction
CFA  thin-cap
broatheroma
D  time domainare being developed by various manufacturers (Lightlab, West-Figure 1. TD OCT and FD OCT: Schematic
(A) Time domain (TD) optical coherence tomography (OCT). Time domain OCT
measures light echoes using a scanning interferometer. A low-coherence, broad-
band light source is split into 2 beams, 1 directed onto the tissue and the other
onto a reference mirror. Interference occurs between backscattered light from the
tissue and light traveling a known echo time delay from the reference mirror.
Interference occurs only when the light from the sample arrives at the same time
as light from the reference path. The magnitude and echo time delay of light from
the tissue is measured by scanning the reference path, generating an axial scan. In
an actual OCT instrument, the interferometer is built using optical ﬁbers, and imag-
ing is performed using an intravascular catheter with a rotating optical ﬁber and
microlens in a transparent sheath. (B) Fourier domain (FD) OCT. Frequency or FD
detection uses a frequency swept light source. The light is directed onto the tissue
and a reference mirror at a ﬁxed delay. Light echoes from different tissue depths
return with different delays, resulting in a frequency difference between the signal
and reference light. The interference produces a beat frequency (equal to this fre-
quency difference) that depends on the echo delay. The beat frequency is mea-
sured by Fourier transforming the signal to recover the echo delay. Each sweep of
the laser, therefore, generates an axial scan. Since all echoes are measured simulta-
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1259ford, Massachusetts; Terumo, Tokyo, Japan; and Volcano,
Rancho Cordova, California) (12).
x Vivo Plaque Characterization
Characterization of plaque type. Fundamental to in vivo use
f OCT is the validation of the technique using histological
ontrols. The earliest study comparing OCT images of
laque with histology and suggesting applications for intra-
ascular imaging was performed in 1996 (7). Comprehen-
ive ex vivo comparisons date from 2002 and are outlined
ith comparisons to IVUS in Table 2. In an initial study,
57 atherosclerotic segments were derived from 90 cadavers,
omprising 162 aortae, 105 carotid, and 90 coronary vessels
13). Three plaque types were identified, as fibrous, fibro-
Table 1. Comparison of IVUS and OCT
IVUS TD OCT FD OCT
Energy wave Ultrasound Near-infrared Near-infrared
Wavelength, m 35–80 1.3 1.3
Resolution, axial/lateral, m 100/200 15/90 15/20–40
Frame rate, frames/s 30 16–20 100
Pullback rate, mm/s 0.5–1.0 1–3 20
Axial scans, 1,000 3.2–4.8 5.4
Lines, axial scans/frame 200–40 500
Maximum scan diameter, mm 10 6.8 9.7
Tissue penetration, mm 10 1–2.5 2.0–3.5
Axial resolution is measured in tissue. Scan diameter is measured in saline for time domain (TD)
optical coherence tomography (OCT) and in contrast medium for Fourier domain (FD) OCT.
Sources: Schuman et al. (2), Morgensen et al. (5), and Jang (11), and Lightlab, Westford, MA.
IVUS intravascular ultrasound.
Table 2. Ex Vivo Plaque Characterization With OCT and IVUS Compared W
Plaque Types
First Author (Ref. #) Lipid Fibrous Calcific
Yabushita et al. (13)
OCT 90/92 96/97 79/97
Kume et al. (14)
OCT 85/94 96/88 79/99
IVUS 59/97 88/86 98/96
Kawasaki et al. (15)
OCT 95/98 98/94 100/100
IVUS 67/95 93/61 100/99
IB IVUS 84/97 94/84 100/99
Rieber et al. (17)
OCT 77/94 67/97 64/88
IVUS 10*/96 63/59* 76/98
Manfrini et al. (16)
OCT 45/83† 83/82 68/76
Numbers indicate percent sensitivity/specificity for detection of each plaque type. *Significant diffe
and Va, indicating lipid plaque. Adapted, with permission, from Chen et al. (3).IB integrated backscatter; other abbreviations as in Table 1.alcific, and lipid rich (Fig. 2). An initial training set of 50
pecimens was used, then the 307 test specimens were
xamined blindly. Identification of fibrocalcific (96%, 97%)
nd lipid-rich (90%, 92%) plaques achieved high sensitivity
nd specificity, respectively, and although sensitivity for
brous plaque was slightly lower (79%), specificity remained
igh (97%); interobserver and intraobserver agreements
ere acceptable (K 0.88 and K 0.91, respectively) (13).
lthough some subsequent studies have demonstrated sim-
lar diagnostic accuracy of OCT examination (14,15), others
ave found lower sensitivities, particularly in the differenti-
tion of lipid from calcific plaque components (16,17)
Table 2). The lower sensitivity may result in part because of
mall sample size or methologic differences (18,19). The
ifferentiation of lipid and calcific plaque may require
xpertise because both are characterized by signal attenua-
ion, wherein the lipid areas have relatively diffuse borders,
nd calcific plaques have sharper edge definition (13,16).
ost studies have been performed using the initial imaging
ystems: validation using FD OCT systems is ongoing, with
he diagnostic accuracy likely to be superior with improved
maging technology.
Characterization of ﬁbrous cap thickness. Given the associ-
tion of cap thickness of 65 m adjacent to the site of
plaque rupture in 95% of cases (20), there is interest in the
bility of OCT to accurately detect fibrous cap thickness
4,12,21,22). Two studies totaling 64 lipid-rich plaques
ave demonstrated close correlation between OCT imaging
nd histology in the assessment of cap thickness (r  0.89
nd r  0.90, p  0.001) (4,21). This represents a unique
bility of OCT for the assessment of high-risk plaques.
tology
Comments
segments from 90 cadavers; included coronary, aorta, carotid; training set of 50
coronary segments, no training set
segments from 17 cadavers; no training set; same readers as the Yabushita group
segments from 8 in situ arteries, multiple images
coronary segments from 15 cadavers; 11-segment training set
comparison between OCT and IVUS (p 0.05). †American Heart Association classification type IVith His
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1260Characterization of thrombus. In initial studies, intralumi-
al thrombus was compared to pathological specimens and
onfirmed as irregular, signal-rich regions (23,24). Using a
easure of signal attenuation, a distinction is possible
etween white (platelet-rich) thrombus with low backscatter
nd red (platelet-poor) thrombus with higher backscatter in
ignal attenuation or shadowing deeper into the thrombus
22). In vivo, this distinction is less evident (12), with
hrombus almost always of a mixed type. Of interest, small
ural thrombi may often be seen.
Characterization of intralesional macrophages. Macro-
phage/foam cells, which are large (diameter: 20 to 30 m)
ells and contain multiple lipid-rich bodies, produce a high
ignal variance from the surrounding tissue to potentially
llow a direct visualization of macrophages with OCT (18).
he normalized standard deviation of the OCT signal
ithin the fibrous cap was used to estimate macrophage
oncentration in lipid-rich plaques and compared with
D68-positive macrophage cell counts assessed immuno-
istochemically; there was a good correlation (r 0.80, p
.001) (18). This is a finding of particular interest, though
learly it is important to recognize that at present, the
esolution is not high enough to recognize individual
acrophages, and such correlations are valid only for
omparisons within plaque and not the vasculature in
eneral, and may be dependent on the OCT system (12,19).
Limitations in image interpretation. Ex vivo histopatholog-
ical correlative studies suggest 2 principal limitations in
Figure 2. Plaque Characterization
Optical coherence tomography images for lipid-rich (A), ﬁbrous (B), and calciﬁ
taining (Ca) regions appear as signal-poor regions within the vessel wall. Lipid
edges. Histological sections: (D and E) Movat pentachrome, (F) hematoxylin a
Yabushita et al. (13).image interpretation. First, the differentiation of lipid from tcalcium deposits may be difficult. Calcium is typically identified
with signal-poor areas, with sharply defined edges; lipid by
similarly signal-poor areas, though with diffuse borders
(13,16). On occasion, the characterization of borders may be
difficult. Second, plaque visualization may be problematic
when fibrous plaque is thick (16). As a result of poor tissue
penetration, it can be difficult to distinguish deep lipid from
attenuated bulky fibrous plaque. For the same reason, it is often
impossible to accurately measure plaque burden and to study
development of neovascularization from adventitia. Whether
such limitations exist with current-generation imaging systems
is under investigation at present.
In Vivo Plaque Characterization
Based on the ex vivo correlative information, there has been
a great interest in the ability of OCT to allow atheroscle-
rotic plaque characterization in vivo, even though it has
limited depth penetration (1 to 2.5 mm) (Fig. 3). Following
the initial proof-of-principle study of OCT in normal pig
coronary vessels in vivo (25), the first human studies were
erformed in 2002 in patients with mild to moderate
therosclerotic lesions (22), which demonstrated the safety
f OCT and efficacy in the identification of the normal
essel wall and plaque components in vivo (22). The
ormal vessel was well seen with OCT as a trilaminar
tructure of intima, media, and adventitia; the media was
isible as a relatively low-signal middle layer (26). On
laque types with corresponding histological sections (D to F). Calcium-con-
laque has diffuse borders, whereas calciﬁc regions have sharply demarcated
sin. Original magniﬁcation  2. Adapted from references Raffel et al. (4) andc (C) p
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1261change, including intimal thickening are also well visu-
alized; these observations form part of a recent consensus
document (26).
Characterization of plaque type. Plaque type identified by
CT has been compared in various patient cohorts (27).
Given the superficial penetration of OCT, lipid-rich plaque
has been defined semiquantitatively only, as lipid compris-
Figure 3. In Vivo Plaque Characterization
(A) Fibrous plaque. Homogeneous high-intensity signal (arrow). (B) Lipid-
laden plaque. Low-intensity, irregular signal with indistinct and irregular
borders (arrow). (C) Calciﬁed plaque. Low-intensity, sharp bordered,
“textured” appearances (marked by the 3 arrows).ing more than 2 quadrants (27). Using this definition, rlipid-rich plaque was identified in 90% of ST-segment
elevation myocardial infarction (STEMI) and 75% of non–
ST-segment elevation myocardial infarction (NSTEMI), as
compared with 60% of stable angina pectoris (SAP)
lesions (p  0.09) (27).
Characterization of ﬁbrous cap thickness. Thin capped fi-
broatheromata (TCFA) are defined pathologically by the
triad of a lipid core, a fibrous cap with a thickness 65 m,
nd inflammatory cell infiltration of the fibrous cap (20).
Interest has therefore focused on the use of OCT for in vivo
assessment of fibrous cap thickness, given the limitations of
IVUS, and OCT’s unique ability to image superficial detail
(4,12). In the ACS patients discussed in the previous text,
TCFA was observed in 72% STEMI and 50% NSTEMI
culprit lesions as compared with 20% SAP lesions (p 
0.01) (27). Presented another way, the same groups exhib-
ted mean fibrous cap thicknesses of 47, 54, and 103 m,
respectively (27). Similar findings have been reported by
ubsequent studies (77% to 83% STEMI, 46% NSTEMI,
nd 3% to 25% SAP; p  0.001) (10). These observations
rovide the first in vivo support for the key postmortem
tudies suggesting the association between ACS and
CFA, and provide 1 of the key advances that OCT has
lready provided as an intracoronary diagnostic tool.
These findings have also suggested the important poten-
ial for using OCT measurements of fibrous cap thickness as
possible marker of plaque vulnerability. In a single-center
rospective study, cap thickness has been shown to increase
n a statin-treated group (28), and in a smaller observational
tudy, patients on statins had fewer plaque ruptures (8% vs.
6%) and had a trend toward increased fibrous cap thickness
78 m vs. 49 m) compared with those not taking statin
29). It is important to recognize that broad clinical out-
ome data are lacking to date, though it would appear
ossible that OCT will be incorporated in future plaque-
tabilization and lipid-lowering therapy trials, with fibrous
ap thickness being a potential surrogate endpoint.
Characterization of plaque rupture. The ability to detect
plaque rupture with OCT has been suggested, and is a
potentially important use of OCT. However, OCT-verified
plaque rupture has been found with somewhat wide varia-
tion between types of ACS in different studies. Rupture has
been observed in 25% to 73% for STEMI, 15% to 42% for
NSTEMI, and 3% to 11% for SAP (10,27). Interestingly, in
the OCT examination of culprit lesions in patients with
ACS that occurs on exertion, OCT demonstrated rupture at
the plaque shoulder in almost all patients, compared with
one-half of the patients with ACS that occurs at rest (p 
0.017), suggesting the mechanisms of plaque rupture may
be distinct between these patients (30). OCT has also
emonstrated that in patients undergoing coronary stenting,
CT-verified TCFA was associated with periprocedural
reatine kinase-MB rise, indicative of procedural plaque
upture or disruption and atheroembolization (31). The
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1262potential for OCT to provide in vivo insights is evident
from such observations, and likely means such lesional
assessments by OCT will be an area of active investigation.
Identiﬁcation of intralesional macrophages. Given the third
component of the pathological definition of TCFA—that of
inflammatory cell infiltration of the fibrous cap—there is
interest in the ability of OCT to identify intralesional
macrophages in vivo. Close correlation with macrophage
density measured by CD68 stain versus OCT image was
possible in selected lesions in vitro as discussed in Tearney
et al. (18). in vivo, macrophage density is increased in ACS
(both STEMI and NSTEMI) compared with SAP (32).
These studies have not yet been replicated with the newer
OCT devices, and depend on selection of a precise area of
interrogation and offline analysis (33,34).
Image artifact. Artifactual images occur with OCT imaging.
asily remedied examples include inadequate blood flushing
rom the vessel, air in the imaging catheter sheath, and
ccentric wire positioning producing a “merry go round” stent
trut appearance. Examples of these and other image artifacts
re illustrated in Figure 4. With increasing use of the novel
CT imaging systems, these and other limitations require
lear identification to maintain image integrity.
Additional information from OCT imaging. There exists the
potential for OCT to identify angiogenesis or neovascular-
ization associated with atheroma. “Black holes” of between
50 and 300 m, present in consecutive frames, appear to
correlate histologically with small vessel formation (26,35),
such that it is possible such information will be sought as
part of OCT-based trials of lesion stabilization. Regarding
OCT in the assessment of saphenous vein graft atheroma,
though this is technically feasible, and has demonstrated
utility in the small numbers studied to date (36,37), whether
flushing under pressure during OCT imaging contributes to
distal embolization remains to be established. If maximum
scan diameters remain at 7 mm, this is also likely to limit
widespread use of OCT in this context. Conversely, early
work imaging arterial radial grafts suggests OCT appears
safe, and has found the potentially important observation of
acute injury and chronic thickening following radial-
approach coronary intervention (38).
OCT and Percutaneous Coronary Intervention:
Immediate Post-Procedural Evaluation
Given the fine resolution at a superficial depth, OCT allows
a uniquely detailed image of the effects of stent implantation
on the vessel wall. OCT allows examination of the target
vessel both pre- and post-intervention (39), defining stent
struts readily, tissue prolapse between stent struts immedi-
ately (40), and tissue characterization of plaque before and
after stent placement (41). The detail provided by the initial
tudies has led to wide interest in tissue prolapse, dissection;
oth intrastent and edge; thrombus; and stent strut malap-osition (42). Many of these appear to occur frequently (42),
nd are illustrated in Figure 5.
Tissue prolapse. Tissue prolapse, or protrusion of tissue
between stent struts without apparent surface disruption, is
defined as occurring if the depth of protrusion is 50 m,
and has been observed almost universally (97.5%) at some
point along the stented segment (42). This high frequency
is similar to postmortem findings (94%) (43), but signifi-
cantly higher than IVUS-verified prolapse of 18% to 35%
(40,44), suggesting OCT is both sensitive and specific. The
clinical significance of such prolapse is, however, unclear,
given that it occurs so frequently, and has not been associ-
ated with early clinical events (42) nor examined in relation
Figure 4. Image Artifact
(A) Blood contamination as a result of inadequate ﬂushing (arrows). There
is a resultant distant image attenuation. (B) Bubble artifact as a result of air
bubbles in the ImageWire sheath. This results in image attenuation
(arrow). (C) “Step-up” or “sew-up” artifact (arrow) as a result of relatively
rapid vessel or wire movement during imaging. (D) Stent strut “merry go
round” as a result of eccentric wire position, most marked with most distal
struts (arrows). (E) Saturation artifact, or blooming, as a result of highly
reﬂectant structures, for example, stent struts (arrows). Examples of wire
position (asterisk) and wire shadow artifact (double asterisks) are
shown in D.to late clinical events.
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1263Intrastent dissection. Intrastent dissection, defined as either
isruption of the vessel surface with dissection flap, or
ssociation with an underlying cavity, has been observed at
similarly high frequency (87.5%), with 86.3% of stented
essels showing a dissection flap and 68.8% showing an
nderlying cavity at some point along their length (42).
n-hospital clinical events were also absent in this group,
eaning their significance—if any—remains to be estab-
ished. Edge dissections were present less commonly
26.3%), with similarly no associated clinical events (42).
or both tissue prolapse and dissection, there was no
ssociation with clinical presentation (42). Edge dissection
s, however, variable, with plaque type as assessed by OCT
eing more frequent in fibrocalcific (43.8%) and lipid-rich
37.5%) compared with fibrous plaque (10%) (26,45).
Stent strut apposition/coverage. Given the precision with
hich OCT visualizes the leading edge of stent struts, and
he lumen–vessel wall interface, the degree of stent strut
pposition is being extensively evaluated using OCT by a
umber of investigators (4,8). A proposed 3-point classifi-
ation defines stent strut apposition as embedded (when the
Figure 5. Immediate Post-Procedural Evaluation
(A) Malapposition. Stent strut malapposition (arrows) is clearly identiﬁed
and can be quantiﬁed. Identifying small degrees of malapposition requires
knowledge of stent strut thickness in that only the leading edge of a
metallic stent strut is demonstrated with optical coherence tomography
(OCT). (B) Stent edge dissection (arrow). Detailed identiﬁcation of dissec-
tion is seen with OCT. (C) Intrastrut prolapse (arrow). Prolapse is deﬁned as
50-m projection of tissue from a line drawn between stent struts and is
readily identiﬁed. (D) Thrombus (arrow): irregular bordered, signal-intense
regions identify thrombus.eading edge is buried within the intima by more thanne-half its thickness), protrusion (when the stent strut is
pposed but not embedded), and malapposed (when there is
o intimal contact) (46,47). Another classification, perti-
nent for follow-up studies examining the degree of neointima
formation, describes whether or not the stent strut appears
covered with tissue, and whether struts are well apposed or
malapposed (48). Stent struts are, therefore, classified as:
) well apposed and covered; 2) well apposed and not covered;
) malapposed and not covered; and 4) malapposed but covered
Fig. 6) (12,48).
The degree of any malapposition has not been widely
uantified, but with newer analysis software, this is easily
erformed, and measurement of the degree or distance of
alapposition in microns is readily possible. Individual
tent struts within sequential image frames are examined
long the stent length, such that large datasets of strut-level
nalyses are generated. These examine stent strut position at
undreds of data points within an individual stent, with the
otential for a more detailed analysis than perhaps even
istology, given this provides information from 0.5- to
-mm intervals between sections (49,50). Such measure-
ments appear to have low intra- and interobserver variabil-
ity, and with a number of software algorithms for quanti-
tative analysis producing detailed stent strut apposition
maps of potentially precise detail, there is the likelihood that
3-dimensional image reconstruction will be achievable,
though clustering of data from individual stents within
larger analyses requires careful statistical consideration (Fig. 7)
Figure 6. Stent Coverage
Enlarged images of individual stent struts illustrating classiﬁcation of stent strut
coverage. (A) Well apposed and covered; (B) well apposed and not covered;
(C) malapposed and not covered; and (D) malapposed but covered.
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1264(8,51–53). In a small series of OCT examinations after
drug-eluting stent (DES) implantation, in which more than
6,000 stent struts were examined, 57.1% struts were embed-
ded, 33.8% were protruding, and 9.1% were malapposed
(46). It is possible that both lesion or stent type plays a role
in malapposition. The clinical relevance of these findings at
present remains unclear.
OCT and PCI: Late Follow-Up
In-stent restenosis: quantiﬁcation. Analysis of the long-term
ffects of stenting at the level of the stent strut is now possible
ith OCT, such that the amount of tissue coverage, degree of
eointimal (NI) thickening, individual strut apposition, and
ssociated findings are being defined in longitudinal studies
nd as endpoints in clinical trials (12,54). Some of these studies
re summarized in Table 3. Though stent strut coverage does
Figure 7. 3-D Stent Strut Analysis Reconstruction
(A) Example of current 3-dimensional (3-D) reconstruction technique. (B)
Example of the results of the algorithm for individual stent strut analysis map-
ping, which color codes the distance of the stent strut from the vessel wall.ot necessarily equate with endothelialization, with this beingelow the resolution of OCT, nor even indicate at present the
issue type, these studies are aimed at optimizing stent perfor-
ance, with modest, uniform, relatively nonprogressive stent
overage being the aim.
Stent strut coverage. Following initial work by Takano and
others, stent strut coverage assessed by OCT has been
performed in a number of studies. In studies comparing
bare-metal stents (BMS) with DES, with follow-up of
between 3 and 7 months, exposed struts with BMS are low
(0.1% to 0.3%) (55,56). For DES, most data are available
for sirolimus-eluting stents, and these have shown higher
exposed strut rates of 4.9% to 17% (56–59), with 1 study
suggesting reduced exposed strut rates with time after stent
placement: 10.4% at 6 months, compared with 5.7% at 12
months (60). DES type may also influence stent coverage,
with both paclitaxel- and zotarolimus-eluting stents exhib-
iting fewer exposed stent struts compared with sirolimus; 1
study has demonstrated a stent strut exposure rate of 0.3% at
9 months with zotarolimus compared with 12% for siroli-
mus (58,59). Zotarolimus-eluting stents may also have low
rates of uncovered stent struts comparable to BMS in the
setting of STEMI (54). Of importance, the ability of OCT
to examine vascular responses, including stent coverage at
sites of stent overlap, has been recently demonstrated, also
suggesting differences between DES types (61,62). Intrigu-
ingly, in an animal study of OCT assessment of stent strut
coverage, there was gradation of decreasing numbers of
uncovered stents progressing distally along the stent, with
41.1%, 35.6%, and 24.3% of uncovered struts in the prox-
imal, mid, and distal thirds of the stents, respectively (63).
It is important to be aware of the variable definition of
strut coverage in various investigations. This is best exem-
plified in the same patient cohort in the LEADERS (Limus
Eluted From A Durable versus ERodable Stent Coating)
OCT substudy of a biolimus degradable polymer-coated
stent; post-implantation lesions were defined as having any
uncovered struts (63.3%), at least 5% uncovered struts
Table 3. Potential Clinical Utility for OCT
OCT recommended
Clinical trial evaluation post-stent
Clinical trial evaluation of novel plaque stabilizing agents
OCT could be considered
Characterization of coronary plaque
Evaluation of immediate post-PCI vascular status: dissection,
stent strut expansion, stent strut apposition, thrombus
Assessment of late stent thrombosis risk: stent strut coverage,
malapposition
Evaluation of other vasculatures: pulmonary, peripheral arterial,
post-transplant vasculopathy
OCT may not be helpful
Assessment of left main stem stenosis severity
Assessment of saphenous vein graft atherosclerosisOCT optical coherence tomography; PCI percutaneous coronary intervention.
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1265(3.8%), or at least 10% uncovered struts (2.2%) (64). The
ormer description may be too sensitive to have clinical
elevance, but the latter may be more useful. Although
istopathological correlations with stent strut coverage are
t an early stage only, a number of important observations
ay already be made. OCT, like IVUS, may overestimate
umen area, and may vary with imaging technique (65) and
ossibly also with software analysis. Following stenting in
ormal pig coronary vessels using FD OCT, there appears
close correlation between OCT images and stent strut
overage assessed by both scanning electron microscopy and
y histology (66). Although an early study with the TD
CT system suggested OCT imaging of shallow NI depths
ay underestimate stent coverage (63), this later work using
D OCT finds good agreement between OCT and histol-
gy in the assessment of NI thickness (r  0.90, p  0.01)
nd stent strut coverage (r  0.96, p  0.01) (66), so that
hese and other studies are providing precision in the
easurement of NI thickness that is at the limit of axial
esolution of OCT at 15 m (59,66,67). Interestingly, in
recent work, the density of the OCT image also provided
useful information, with low-intensity signal that covers
stent struts associated by scanning electron microscopy with
fibrin, progressing to a higher-density signal, associated
with NI formation by scanning electron microscopy, with
increasing time post stent (66). Studies of this type show the
potential for OCT to provide important insights into the
pathobiological responses to stenting in vivo in the athero-
matous human coronary.
Stent strut apposition. Malapposition was first defined as
ack of contact between stent strut and intima, in a clinical
etting, using IVUS criteria (68,69). To be used in OCT
imaging, this requires recognition that only the leading edge
of the stent strut is visible with OCT, such that precise
definition of malapposition requires knowledge of stent
geometry and thickness. This is pertinent, given that stent
strut diameter varies, for example, Cypher (sirolimus; Cor-
dis Corporation, Bridgewater, New Jersey)  154 m,
Taxus (paclitaxel; Boston Scientific, Natick, Massachusetts) 
127 m, Endeavor (zotarolimus; Medtronic, Minneapolis,
Minnesota)  107 m, Xience (everolimus; Abbott Vascu-
lar, Santa Clara, California)  88 m. To date, there has
een variation between study definitions (60,70), so that
consensus in this area is currently being sought. However,
such discussions again reflect the intravascular detail that
OCT imaging is capable of providing.
The denominator of malapposed stent struts also varies
between studies, variously being total stent struts or
stented lesions (64,71). A common definition is the
percentage of malapposed stent struts compared with
total stent struts, and has been found to be between 0.2%
and 2.6% for DES (59,71). Zotarolimus-eluting stents
may have lower rates of malapposition compared with
sirolimus (0.2% vs. 2.6% at 9 months) (59), and sirolimusmay have a reducing rate of malapposition between 5 and
43 months (1.4% vs. 0.3%) (71).
Thrombus. Small areas consistent with intraluminal throm-
bus have been observed at follow-up after stenting using
OCT. Given the limited ability of IVUS in this context, and
recognition of ongoing risks of late stent thrombosis, these
observations are of interest. Such thrombi are relatively
small, and generally adjacent to the intima. Reported rates
vary between 5.9% and 27.8% for sirolimus-eluting stents
and 11% for paclitaxel-eluting stents (58,59,71–73); how-
ever, the sample size in all these studies has been very
limited. Most of these studies have been within 1 year, with
patients predominantly on dual antiplatelet therapy of
aspirin and clopidogrel (58,59,72,73). The potential for
CT to detect the increased thrombotic risk later after
ES is likely to be an area of ongoing interest.
Correlation with clinical outcomes. Of importance, how the
OCT indexes of stent coverage, malapposition, thrombus,
and NI formation correlate with clinical outcomes is not
known. Interestingly, although zotarolimus-eluting stents
have shown a higher rate of stent coverage compared with
sirolimus-eluting stents at 9 months (59), this has not
translated into improved clinical outcomes (74). Similarly,
OCT-diagnosed intrastent thrombus—which might be ex-
pected to relate to minimal NI and uncovered stent struts—
has shown no relationship to NI thickness (75). Such
correlation of OCT findings with clinical outcomes is thus
likely to be an area of ongoing investigation, with OCT
substudy analyses of larger clinical trials already underway or
reported. Such studies are likely to play an important role in
advancing OCT from a research to a clinical tool.
In-stent restenosis: characterization. It has been suggested
that OCT may provide characterization of in-stent reste-
nosis tissue (76–78). In limited clinical studies to date,
predominantly following DES, in-stent restenosis material
has been described as uniformly homogeneous or heteroge-
neous; layered, with signal attenuation that may be gradual
or rapid; or almost uniformly hypodense (76–79). Variation
in appearance suggests variation in tissue composition.
Pathological studies of human atherectomy specimens of
in-stent restenosis tissue post-DES have shown a variety of
tissue types, including smooth muscle cells, proteoglycan-
rich myxomatous material, thrombus, and fibrinoid material
(80). Substantial pathological correlates with OCT findings
are not available, though in anecdotal reports, OCT regions
of hypodense signal are related to myxomatous tissue, and
hyperdense regions related to smooth muscle cell–rich NI
(81); in a porcine study, hypodense OCT signal was
associated with fibrinoid and proteoglycan material located
in the peristent strut region (82). This capability of OCT to
rovide insight into histopathological changes following
tenting, though preliminary, is of potentially great interest.
De novo atherosclerosis post-stenting. Of particular interest
are recent observations of long-term follow-up (5 years)
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1266following bare metal stenting. In patients with OCT per-
formed 5 years post-stent compared with patients with
6 months post-stent, OCT appearances suggest impor-
tant differences (83). The late group had relatively high rates
of lipid-laden intima, intimal disruption, and thrombus
formation (67% vs. 0%, 38% vs. 0%, and 52% vs. 5%,
respectively). Presumed intraluminal neovascularization was
also more commonly seen in the late group (62% vs. 0%)
and more commonly associated with lipid-laden intima than
nonlipid-associated tissue (79% vs. 29%) (83). In separate
studies, similar lipid-rich plaque has been observed in
one-third of stents (16 of 39 patients) at 6.5  1.3 years
ollowing BMS in patients presenting with recurrent isch-
mia (84). Interestingly, in these patients, the fibrous cap
as also relatively thin (57.7  5.8 m) and widespread
(lipid arc: 173° 58°), and a smaller number of patients had
evidence of recent plaque rupture or mural thrombus (84).
Interestingly, angioscopy and histopathological studies pro-
vide supportive evidence for similar observations after DES
(85,86); in-stent de novo atherosclerosis was much more
aggressive and occurred earlier with DES. Angioscopy has
demonstrated increased yellow (i.e., lipid-containing)
plaques in late (4 years) follow-up after BMS compared
ith increased white (i.e., fibrous) plaque at early (6 month)
ollow-up (85). Histopathological studies have demonstrated
ipid-laden macrophage accumulation within NI formation
fter BMS and DES, with that in DES peaking at 1 year, and
hat following BMS only seen after 4 to 5 years (86). It is,
herefore, conceivable that late OCT examination post-stent
ill provide useful pathobiological insight.
tudy Limitations
A number of important limitations remain with OCT. A
principal limitation is the need to displace blood or dilute
the hematocrit, either with saline or contrast flush injection,
or a combination of the two. Motorized imaging pullback
has been a significant advance with FD systems, enabling
efficient imaging during injection and is likely to see further
improvement. However, the limitation of requiring a blood-
free field is likely to remain in the near future, given that
blood strongly scatters light. A second principal limitation
to OCT is the shallow image penetration of 1 to 2.5 mm
(26). This prevents assessments of cross-sectional plaque
area, which may mean that OCT has only a limited role in
the assessment of left main stem and saphenous vein graft
atherosclerosis severity (87). Imaging the peripheral arterial
bed has also not been reliable, particularly with the earlier
generation systems. In addition, some aspects of plaque
characterization still present difficulties with OCT. The
differentiation of calcific areas from lipid pools can be
problematic (16,26). Both result in a low attenuation signal,
though lipid often has a more irregular border, but in direct
comparisons with postmortem human samples, image in-terpretation may be difficult (16). Last, image artifacts do
occur, including incomplete blood displacement; “sew-up”
malalignment of the vessel as a result of excessive vessel or
wire movement relative to imaging speed; image attenuation
as a result of air; and others, well described previously (12).
The Potential for Clinical Utility
OCT is at present an investigative tool for intravascular
imaging, providing unique detail of relatively superficial
intravascular structure. At a practical level, it is easily
incorporated into interventional procedures, with minimal
additional training, and has recently gained widespread
regulatory approval. Although these features mean OCT is
likely to see increasingly widespread use, it is at present
important to critically evaluate how this unprecedented view
of coronary biology is likely to alter management.
Importantly, outcome data correlating OCT findings
with subsequent events is not yet available. This is likely to
come from 2 sources. First, clinical trial OCT data are
already available on small groups of patients, including those
from the ABSORB (a fully absorbable everolimus-eluting
stent scaffold: n  30, follow-up to 3 years) (88), and
ODESSA (Optical coherence tomography for DES
SAfety) trials (overlapping DES and BMS, n  71, follow-
p: 6 months) (61). These studies demonstrate the precision
ith which OCT is capable of examining the vascular
esponse to stent placement. Second, close registry
ollow-up of patients undergoing OCT may provide further
mportant outcome data. One such multicenter registry aims
o collate clinical and OCT registry data in 3,000 or more
atients, with systematic follow-up for 5 years. This type of
linical trial and registry data will provide opportunities to
ompare structural changes detected by OCT with clinical
utcomes and will be important in establishing whether or
ot OCT proceeds to a clinically relevant imaging tool.
Some broad comments regarding the clinical use of OCT
an be made, however, and are summarized in Table 3.
OCT is likely to be useful in the clinical trial evaluation of
novel stents and plaque-stabilizing and lipid-lowering
drugs, as the information provided by OCT is of particular
relevance in these settings and is unique. By contrast, as a
result of the requirement for a blood-free field and the poor
image penetration, OCT of aorto-ostial lesions, particularly
the left main, has not yet proven useful. The use of OCT in
saphenous vein graft assessment remains to be established.
In the middle ground, in situations where OCT may have a
role and be considered, are a large number of potential areas.
These include the guiding of complex interventions and
stent placement, assessment of NI formation, evaluation of
stent thrombosis, and in plaque characterization and possi-
ble risk stratification. Although OCT clearly provides de-
tailed images in these situations, a crucial clinical question is
whether OCT will replace IVUS for these and similar
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1267contexts. A key factor in this consideration is that data
supporting OCT will need to demonstrate improved patient
care and improved outcomes. Such indications where this
might be foreseen include pre-PCI plaque evaluation; im-
mediate post-PCI evaluation, and assessment of late stent
thrombosis. From such considerations, it is clear OCT
might either remain a niche-only imaging modality con-
fined to the research arena, or alternatively, evolve into a
widely used clinical tool. Investigations in the next few
years are likely to be of key importance in determining
the ultimate acceptance of intracoronary OCT.
Future Directions and Technical Considerations
OCT is likely to see a number of further developments in
the near future, particularly in 2 broad areas. First, widened
clinical indications are likely to be explored; some examples
include settings of increased NI formation, such as pulmo-
nary hypertension (89), or post-transplantation vasculopa-
hy. Second, a number of technological advances are under
ctive investigation and are expected to yield improved
maging times and image quality for intravascular OCT.
esearch FD OCT technology has been demonstrated with
00,000 axial scans/s for small animal endoscopic imaging,
nd acquisition speeds of more than 1 million scans/s have
een achieved in bench-top systems using a special swept
aser technology (90,91). Future commercial OCT intravas-
ular instruments can be expected to have increases of 2 to
 the axial scan rates—up to 100,000 to 200,000 axial
cans/s. However, intravascular imaging requires mechani-
al rotation of the catheter imaging optics to generate
-scans, meaning the maximum frame rate (B-scans/s) will
ikely be limited by the mechanical constraints of catheter
otation. Current intravascular OCT catheters image at 100
rames/s, corresponding to 6,000 rotations per minute. It
hould be feasible to increase the catheter rotation speeds by
2 and achieve imaging speeds of approximately 200
rames/s. This increased frame rate will in turn enable a
aster pullback speed to image longer segments of the
rteries or shorten the procedure time.
Three-dimensional volumetric OCT datasets provide a
arge amount of data, and improvements in automated
mage processing can be expected, which will aid in inter-
retation and analysis (33,47). Parameters, such as sent strut
pposition and NI thickness can be readily identified in
CT images and quantitatively measured. However, more
ubtle morphological parameters, such as fibrous cap thick-
ess, or compositional parameters, such as plaque type, can
e more challenging to automate and may still require
rained reader interpretation. Automated classification soft-
are is especially challenging to develop because of the
ange of possible morphologies and the requirement that the
lgorithms achieve sufficient sensitivity and specificity
enchmarks to be clinically useful.A variety of functional OCT imaging techniques are also
nder investigation. Elastography has been used in IVUS,
nd analogous techniques are being developed with OCT
92–95). Elastography measures tissue mechanical proper-
ies using differences in B-scan images or A-scan acquired at
ifferent points in the cardiac cycle. Mechanical properties
re an important parameter for the assessment of vulnerable
laque. However, the rapid imaging speeds of intravascular
CT makes this technique challenging because images are
cquired rapidly compared with arterial pressure changes.
oppler techniques operate by measuring the changes in the
hase of the backscattered light to detect motion. Doppler
96) and polarization-sensitive (97) OCT have been devel-
ped and are finding increased use in other specialties, such
s ophthalmology. Doppler flow measurements can be
ntegrated with OCT catheter-based structural imaging
98). However, intravascular Doppler OCT is challenging
ecause the optical scattering of blood limits imaging
epths, preventing Doppler assessment of the entire cross-
ectional luminal flow. In addition, typical OCT imaging
atheters would produce perturbations of normal flow.
olarization-sensitive OCT is a promising technique that
nhances tissue contrast and specificity by measuring the
olarization properties of the backscattered light (99). Last,
t is also possible that the use of various macrophage or other
ellular targeting agents labeled with fluorophores, such as
nnexin A5 and other compounds, may allow better char-
cterization of fibrous cap characteristics using hybrid opti-
al systems (100).
onclusions
OCT is an elegant intravascular imaging modality with
unique characteristics, which is already aiding a better
understanding of vascular biology. OCT provides detailed
structural information, including the vascular responses to
PCI, and is establishing itself as a niche device in the
evaluation of therapeutic interventions. Importantly,
whether this new technology will improve patient care,
remains to be seen, and large prospective studies and registry
data are already being collected to answer this question.
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